Skip to main content

Delgocitinib FDA Approval Status

Last updated by Judith Stewart, BPharm on Oct 30, 2024.

FDA Approved: No
Generic name: delgocitinib
Dosage form: Topical Cream
Company: LEO Pharma Inc.
Treatment for: Chronic Hand Eczema

Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor in development for the treatment of moderate to severe chronic hand eczema.

Development timeline for delgocitinib

DateArticle
Sep 23, 2024FDA Accepts LEO Pharma’s Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema
Oct 13, 2023LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.